Clin Mol Hepatol.
2014 Jun;20(2):218-222. 10.3350/cmh.2014.20.2.218.
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
- Affiliations
-
- 1Department of Radiology, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea, Seoul, Korea.
- 2Department of Radiological Sciences, University of California, Irvine, Orange, CA, USA. clall@uci.edu
- 3Department of Hepatobiliary Surgery, University of California, Irvine, Orange, CA, USA.
- 4Department of Radiological Sciences, MD Anderson Medical Center, Houston, TX, USA.
- 5Department of Radiology, VA Puget Sound, University of Washington, Seattle, WA, USA.
- 6Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, USA.
- 7Department of Oncology, University of California, Irvine, Orange, CA, USA.
- KMID: 1788573
- DOI: http://doi.org/10.3350/cmh.2014.20.2.218
Abstract
- Hepatocellular carcinomas are highly vascular tumors, showing progressive hypervascularity by the process of neoangiogenesis. Tumor angiogenesis is critical for tumor growth as well as metastatic spread therefore, imaging and quantification of tumor neo-angiogenesis is essential for monitoring response to targeted therapies and predicting disease progression. Sorafenib is a molecular targeting agent used for treating hypervascular tumors. This drug is now the standard of care in treatment of patients with advanced hepatocellular carcinoma. Due to its anti-angiogenic and anti-proliferative actions, imaging findings following treatment with Sorafenib are quite distinct when compared to conventional chemotherapeutic agents. Liver MRI is a widely adopted imaging modality for assessing treatment response in hepatocellular carcinoma and imaging features may reflect pathophysiological changes within the tumor. In this mini-review, we will discuss MRI findings after Sorafenib treatment in hepatocellular carcinoma and review the feasibility of MRI as an early biomarker in differentiating responders from non-responders after treatment with molecular targeting agents.
Keyword
MeSH Terms
-
Aged
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/drug therapy/physiopathology/*radiography
Female
Humans
Liver Neoplasms/drug therapy/physiopathology/*radiography
*Magnetic Resonance Imaging
Male
Middle Aged
Niacinamide/*analogs & derivatives/therapeutic use
Phenylurea Compounds/*therapeutic use
Tomography, X-Ray Computed
Antineoplastic Agents
Phenylurea Compounds
Niacinamide
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Complete Response of Single Nodular Large Hepatocellular Carcinoma with Pulmonary Metastasis by Sequential Transarterial Chemoembolization and Sorafenib: A Case Report
- The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma
- Liver resection after sorafenib therapy in advanced hepatocellular carcinoma: a case report
